Platelet reactivity with a third generation thienopyridine drug versus with a second-generation thienopyridine drug

Abstract

Prasugrel is a third generation thienopyridine drug and Clopidogrel is a second-generation thienopyridine drug. Both drugs used for reducing platelet aggregation in patients with coronary artery diseases. The aim of this study is to investigate the antiplatelet efficacy and safety of Prasugrel 5mg daily as compared to Clopidogrel 75 mg daily for period along to 12 days treatment. Fifty patients, (10 females, 40 males), their ages ranging from (50-60) years with stable angina were recruited from IbnAlbitar Center for Cardiac Surgery and enrolled in this case study. Of whom 25 patients (group A) received a dose of 75 mg daily of Clopidogrel and other 25 patients (group B) were on  a dose of 5 mg daily of Prasugrel for a period of 12 days. Clinical laboratory data of lipid profile, renal function, and prothrombine time obtained at baseline (before treatment). While Platelet aggregation percent measured at the baseline and after 12 days of treatment. The maximal platelet aggregation percent for group A was fell from 78 % ± 6.3 (baseline) to 43.5% ± 5.8 (after 12 days treatment). While patients of group B showed dropping in the maximal platelet aggregation percent from 76% ± 7.4 (baseline) to 27.3% ± 5.7 (after 12 days treatment). Analysis of adverse events showed three patients with minor bleeding occurred during Prasugrel treatment, and no bleeding occurred during Clopidogrel treatment. Compared with Clopidogrel 75mg treatment, Prasugrel 5mg treatment for 12 days averted platelets accumulation more quickly and steadily.